Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
MEEQ, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 63%, Oct-Dec Ordinary Profit Increases by 2.1 times
332A MEEQ Inc. 【J-GAAP】
Earnings ReportMEEQ Inc. <332A> [TSE Growth] announced its financial results after the market closed on February 13th (15:30). The consolidated ordinary profit for the cumulative third quarter of the fiscal year ending March 2026 (April to December) expanded 1.13 billion yen, an increase 63.2% compared to the previous period non-consolidated. Progress toward the full-year plan of 1.20 billion yen was 94.7%, also surpassing progress of 76.5% from the same period of the previous year.
Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the January to March period (4Q) is expected to significant drop 70.1% from the previous period non-consolidated to 0.06 billion yen.
In the most recent three-month period, from October to December (3Q), the consolidated ordinary profit surged 2.1 times that of the same period last year, reaching 0.46 billion yen. The operating profit margin jumped from 15.0% in the same period last year to 23.8%.
Note: Since of the current fiscal year, the company has transitioned to consolidated financial statements.
Kabutan News
Actual Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Progress Rate vs. First Half | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Apr - Dec, 2024 | 4,202 | 697 | 696 | 456 | 47.0 | 76.5 | Mar 21, 2025 | J-GAAP |
| Apr - Dec, 2025 | 5,409 | 1,129 | 1,136 | 762 | 66.7 | 94.7 | Feb 13, 2026 | J-GAAP |
| YoY | +28.7% | +62.0% | +63.2% | +67.1% | +41.8% |
Current Period Guidance
Second Half Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Mar, 2024 | 3,269 | 457 | 438 | 323 | 33.1 | 0 | May 15, 2025 | J-GAAP |
| Oct - Mar, 2025 Guidance | 3,546 | 526 | 533 | 388 | 33.9 | 0 | Nov 13, 2025 | J-GAAP |
| YoY | +8.5% | +15.1% | +21.7% | +20.1% | +2.5% |
Current Period Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Mar, 2025 | 5,974 | 929 | 910 | 633 | 64.8 | 0 | May 15, 2025 | J-GAAP |
| Mar, 2026 Guidance | 7,000 | 1,190 | 1,200 | 820 | 71.6 | 0 | Nov 13, 2025 | J-GAAP |
| YoY | +17.2% | +28.1% | +31.9% | +29.5% | +10.5% |
Quarterly Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Dec, 2024 | 1,497 | 225 | 224 | 146 | 15.1 | 15.0 | Mar 21, 2025 | J-GAAP |
| Jan - Mar, 2025 | 1,772 | 232 | 214 | 177 | 18.1 | 13.1 | May 15, 2025 | J-GAAP |
| Apr - Jun, 2025 | 1,711 | 329 | 328 | 215 | 18.8 | 19.2 | Aug 12, 2025 | J-GAAP |
| Jul - Sep, 2025 | 1,743 | 335 | 339 | 217 | 19.0 | 19.2 | Nov 13, 2025 | J-GAAP |
| Oct - Dec, 2025 | 1,955 | 465 | 469 | 330 | 28.9 | 23.8 | Feb 13, 2026 | J-GAAP |
| YoY | +30.6% | +106.7% | +109.4% | +126.0% | +91.8% |
Related Articles
SECURE, 2.0 times Increase in Ordinary Profit, Update Record High for Fourth Consecutive Term
Kubota Pharma, Last Fiscal Year's Net Income Loss Narrows, Current period performance is undisclosed.
eGuarantee, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 5%, Oct-Dec Ordinary Profit Increases by 3%
Cuorips, Ordinary Profit Forecast for the Fiscal Year Loss Widened in Downward Revision
Nxera Pharma, Last Fiscal Year's Net Income Loss Widens, Current period performance is undisclosed.
Thinca, The Current Fiscal Year's Net Income Turns to Loss
OPTORUN, 2.3 times Increase in Ordinary Profit for The Current Fiscal Year, Dividend Raised by 2 Yen
NOVARESE, 89% Increase in Net Income for the Last Fiscal Year, Current period performance is undisclosed.
EYEZ INC, Ordinary Profit/Loss Unexpectedly Turn to Loss for Last Fiscal Year, Returning to Profitability This Year
WILSON LEARNING WORLDWIDE, Apr-Dec (Cumulative 3Q) Ordinary Profit Loss Narrows, Oct-Dec Ordinary Profit Loss Narrows